Matthew Fuller, Ph.D.

Vice President – Head of Gene Therapy Research at Ultragenyx

Matthew Fuller is Vice President – Head of Gene Therapy Research at Ultragenyx, leading execution of program and platform research to continually optimize and invest in Ultragenyx’s gene therapy platforms and programs. Matthew also serves on the FNIH Bespoke Gene Therapy Consortium, as a member of the scientific advisory board for the Coalition to Cure CHD2, as a member of the scientific advisory board for IDefine and as chief scientific advisor for the Cohen Syndrome Research Foundation. Matthew received a PhD from the University of Missouri – Columbia and a MSPH from Tulane University.